Evolus Faces Heightened Operational Risk from Overseas Manufacturing and Disaster Recovery Gaps

Evolus, Inc. (EOLS) has disclosed a new risk, in the Supply Chain category.

Evolus, Inc. faces significant operational risk because it depends on third‑party licensors with manufacturing facilities located outside the U.S. If these facilities are damaged, disrupted, or fail to meet regulatory standards, product supply could be delayed or halted.

Such interruptions could impair clinical development timelines and commercialization efforts, materially harming Evolus’s business, financial results, and reputation. Moreover, any shortcomings or failures in disaster recovery and business continuity plans could lead to substantial additional costs and prolonged downtime.

The average EOLS stock price target is $14.50, implying 127.63% upside potential.

To learn more about Evolus, Inc.’s risk factors, click here.